All Oncology News

Shirley Michelle Shiller, DO, discusses the clinical application of precision medicine in gastrointestinal cancer.

Jarushka Naidoo, MBBCh, discusses the toxicities associated with the use of immunotherapy in oncology, optimal methods of managing them, and the growing body of knowledge on why they occur.

Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

The FDA has accepted a supplemental biologics license application for dasatinib for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Thomas Herzog, MD, traces the therapeutic evolution of frontline treatment for patients with ovarian cancer.

Julie R. Brahmer, MD, provides an overview of the landscape of metastatic non–small cell lung cancer, specifically addressing the combination immunotherapy studies with the greatest impact.

Elias Jabbour, MD, discusses recent clinical trial results in acute lymphoblastic leukemia , the role of immunotherapy, and the biggest challenges facing the field.

Amit G. Singal, MD, discusses the evolving armamentarium of treatment options for patients with hepatocellular carcinoma.

Matthew J. Ellis, MD, PhD, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.

The European Commission has approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant treatment of patients with BRAF V600–positive stage III melanoma.

The European Commission has approved blinatumomab for the treatment of pediatric patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia that is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.

Banu K. Arun, MD, discusses the challenge of treating patients with TNBC and BRCA1-related breast cancers, the value of genotyping, and what she hopes to see in future trial results.

Angeles Alvarez Secord, MD, discusses recent updates in ovarian cancer, with an emphasis on the clinical significance of genetic testing.

Maryam Nemati Shafaee, MD, discusses the pivotal trials in breast cancer that were reported at the 2018 ASCO Annual Meeting.

Sara M. Tolaney, MD, MPH, discusses developments in the treatment paradigms for patients with HR-positive or HER2-positive breast cancer.

D. Ross Camidge, MD, PhD, discusses the use of immunotherapy in patients with non–small cell lung cancer.

Sunil Verma, MD, shares insight on the benefits and unanswered questions that remain with biosimilars in oncology.

Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

The European Commission has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

A supplemental new drug application has been submitted to the FDA for a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma.

The Association of Community Cancer Centers will honor the recipients of 2018 ACCC Innovator Awards at the ACCC 35th National Oncology Conference, October 17-19 in Phoenix, Arizona, where this year’s honorees will share strategies and lessons learned from their own experience to enable others to model and scale similar initiatives.

The European Commission has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.

The FDA has approved ibrutinib in combination with rituximab for the treatment of patients with Waldenström macroglobulinemia.

Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.

A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.

Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.